

CONTACTS:

Brent Larson,
Vice President / CFO
614 822 2330

Tim Ryan,
The Shoreham Group
646 342 6199

NEOPROBE INTRODUCES HIGH ENERGY PROBE
Compatible with Existing Neoprobe Control Units

DUBLIN, OHIO – March 5, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it introduced a new high energy gamma detection probe at the Society of Surgical Oncology's 62nd Annual Cancer Symposium currently underway at the Phoenix Convention Center in Phoenix, Arizona. The new probe is intended for the detection of high energy radioactive isotopes, such as Fludeoxyglucose F 18 (FDG), in surgical oncology procedures. The new high energy probe is compatible with all models of the Company's neo2000[®] and neoprobe[®] GDS systems sold since January 2004.

David Bupp, Neoprobe's President and CEO, said, "We are excited by this addition to our line of gamma detection probes. We believe the addition of a probe capable of identifying high energy radionuclides will expand the medical applications in which our products can be used. The new probe offers the surgeon the advantages of being able to identify tissue containing radionuclides such as FDG in real time during surgical oncology procedures and may be used on connection with Positive Emission Tomography (PET) scans which are gaining popularity in cancer diagnosis and treatment. Because the high energy probe may be used with the majority of our existing installed base of neoprobe GDS and neo2000 system control units, we believe our current customers as well as those considering the purchase of a gamma detection system will be excited about the potential of this new offering. We expect that the first commercial shipments of the probe will occur around mid-year 2009. The probe and control unit offerings we have launched over the last year, coupled with our clinical development programs for the lymphatic tissue tracing agent Lymphoseek[®] and colorectal drug RIGScan[®] CR, demonstrate Neoprobe's commitment to assist physicians in providing state of the art treatment for cancer patients."

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe[®] GDS line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix[®] line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek[®] and RIGScan[®] CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.

www.neoprobe.com